{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:48:45Z","timestamp":1791413325731,"version":"4.3.3"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Until recently, human coronaviruses (HCoVs), such as HCoV strain OC43 (HCoV-OC43), were mainly known to cause 15 to 30% of mild upper respiratory tract infections. In recent years, the identification of new HCoVs, including severe acute respiratory syndrome coronavirus, revealed that HCoVs can be highly pathogenic and can cause more severe upper and lower respiratory tract infections, including bronchiolitis and pneumonia. To date, no specific antiviral drugs to prevent or treat HCoV infections are available. We demonstrate that chloroquine, a widely used drug with well-known antimalarial effects, inhibits HCoV-OC43 replication in HRT-18 cells, with a 50% effective concentration (\u00b1 standard deviation) of 0.306 \u00b1 0.0091 \u03bcM and a 50% cytotoxic concentration (\u00b1 standard deviation) of 419 \u00b1 192.5 \u03bcM, resulting in a selectivity index of 1,369. Further, we investigated whether chloroquine could prevent HCoV-OC43-induced death in newborn mice. Our results show that a lethal HCoV-OC43 infection in newborn C57BL\/6 mice can be treated with chloroquine acquired transplacentally or via maternal milk. The highest survival rate (98.6%) of the pups was found when mother mice were treated daily with a concentration of 15 mg of chloroquine per kg of body weight. Survival rates declined in a dose-dependent manner, with 88% survival when treated with 5 mg\/kg chloroquine and 13% survival when treated with 1 mg\/kg chloroquine. Our results show that chloroquine can be highly effective against HCoV-OC43 infection in newborn mice and may be considered as a future drug against HCoVs.<\/jats:p>","DOI":"10.1128\/aac.01509-08","type":"journal-article","created":{"date-parts":[[2009,6,9]],"date-time":"2009-06-09T01:49:59Z","timestamp":1244512199000},"page":"3416-3421","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":246,"title":["Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice"],"prefix":"10.1128","volume":"53","author":[{"given":"Els","family":"Keyaerts","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Vijgen","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Rysman","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannick","family":"Verbeeck","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Van Ranst","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Maes","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00007691-198802000-00004","volume":"10","year":"1988","unstructured":"Akintonwa, A., S. A. Gbajumo, and A. F. Mabadeje. 1988. Placental and milk transfer of chloroquine in humans. Ther. Drug Monit.10:147-149.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_2_3_2","first-page":"443","volume":"40","year":"1983","unstructured":"Akintonwa, A., M. C. Meyer, and M. K. Yau. 1983. Placental transfer of chloroquine in pregnant rabbits. Res. Commun. Chem. Pathol. Pharmacol.40:443-455.","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.19.8913-8921.2000"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20288"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000457522","volume":"17","year":"1991","unstructured":"Augustijns, P., H. W. Jongsma, and N. Verbeke. 1991. Transplacental distribution of chloroquine in sheep. Dev. Pharmacol. Ther.17:191-199.","journal-title":"Dev. Pharmacol. Ther."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020601700505"},{"key":"e_1_3_2_8_2","first-page":"193","year":"2001","unstructured":"Blau, D., and K. V. Holmes. 2001. Human coronavirus HCoV-229E enters susceptible cells via the endocytic pathway, p. 193-197. In E. Lavi (ed.), The nidoviruses, coronaviruses and arteriviruses. Kluwer, New York, NY.","journal-title":"The nidoviruses, coronaviruses and arteriviruses"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1097\/00002030-200111090-00024","volume":"15","year":"2001","unstructured":"Boelaert, J. R., S. Yaro, P. Augustijns, N. Meda, Y. J. Schneider, D. Schols, R. Mols, E. A. De Laere, and P. Van de Perre. 2001. Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. AIDS15:2205-2207.","journal-title":"AIDS"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/430301"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/506350"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/clinchem\/28.5.1148","volume":"28","year":"1982","unstructured":"Essien, E. E., and G. C. Afamefuna. 1982. Chloroquine and its metabolites in human cord blood, neonatal blood, and urine after maternal medication. Clin. Chem.28:1148-1152.","journal-title":"Clin. Chem."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0400762101"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.15.7863-7866.2004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4615-1325-4_16","volume":"494","year":"2001","unstructured":"Jacomy, H., and P. J. Talbot. 2001. Susceptibility of murine CNS to OC43 infection. Adv. Exp. Med. Biol.494:101-107.","journal-title":"Adv. Exp. Med. Biol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0042-6822(03)00323-4","volume":"315","year":"2003","unstructured":"Jacomy, H., and P. J. Talbot. 2003. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology315:20-33.","journal-title":"Virology"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.085"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2007.10.011","volume":"77","year":"2008","unstructured":"Kono, M., K. Tatsumi, A. M. Imai, K. Saito, T. Kuriyama, and H. Shirasawa. 2008. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antivir. Res.77:150-152.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_19_2","first-page":"149","volume":"15","year":"1986","unstructured":"Kouroumalis, E. A., and J. Koskinas. 1986. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann. Acad. Med. Singapore15:149-152.","journal-title":"Ann. Acad. Med. Singapore"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030781"},{"key":"e_1_3_2_21_2","first-page":"1163","year":"2001","unstructured":"Lai, M. M. C., and K. V. Holmes. 2001. Coronaviridae: the viruses and their replication, p. 1163-1185. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA.","journal-title":"Fields virology"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890050306"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02614-05"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-2478(98)00096-0","volume":"64","year":"1998","unstructured":"Pardridge, W. M., J. Yang, and A. Diagne. 1998. Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Immunol. Lett.64:45-47.","journal-title":"Immunol. Lett."},{"key":"e_1_3_2_25_2","first-page":"474","volume":"70","year":"1963","unstructured":"Rubin, M., H. N. Bernstein, and N. J. Zvaifler. 1963. Studies on the pharmacology of chloroquine. Recommendations for the treatment of chloroquine retinopathy. Arch. Ophthalmol.70:474-481.","journal-title":"Recommendations for the treatment of chloroquine retinopathy. Arch. Ophthalmol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00806-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1386-6532(00)00139-6","volume":"20","year":"2001","unstructured":"Savarino, A., L. Gennero, K. Sperber, and J. R. Boelaert. 2001. The anti-HIV-1 activity of chloroquine. J. Clin. Virol.20:131-135.","journal-title":"J. Clin. Virol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1089\/jir.1996.16.725","volume":"16","year":"1996","unstructured":"Singh, A. K., G. S. Sidhu, R. M. Friedman, and R. K. Maheshwari. 1996. Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine. J. Interferon Cytokine Res.16:725-731.","journal-title":"J. Interferon Cytokine Res."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/aid.1990.6.481","volume":"6","year":"1990","unstructured":"Tsai, W. P., P. L. Nara, H. F. Kung, and S. Oroszlan. 1990. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res. Hum. Retrovir.6:481-489.","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1024"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02675-05"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.04.010"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.11.5452-5456.2005"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.3.1595-1604.2005"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-69"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.2.884-895.2005"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/497151"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01509-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01509-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:17:53Z","timestamp":1645474673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01509-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1128\/AAC.01509-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01509-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"2008-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}